233
Participants
Start Date
November 2, 2017
Primary Completion Date
November 8, 2019
Study Completion Date
December 11, 2020
DS-8201a
DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
Physician's Choice
"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
National Cancer Center, Ilsan
Seoul National University Bundang Hospital, Seongnam
Gachon University Gil Medical Center, Incheon
Chungbuk National University Hospital, Cheongju-si
Kyungpook National University Chilgok Hospital, Daegu
Inje University Haeundae Paik Hospital, Busan
Dong-A University Hospital, Busan
Chonbuk National University Hospital, Jeonju
Chonnam National University Hwasun Hospital, Gwangju
Aichi Cancer Center Hospital, Nagoya
Hirosaki University Hospital, Hirosaki
National Cancer Center Hospital East, Kashiwa
National Hospital Organization Shikoku Cancer Center, Matsuyama
Japan Community Health Care Organization Kyushu Hospital, Kitakyushu
Gunma Prefectural Cancer Center, Ōta
Kure Medical Center, Kure
Hokkaido University Hospital, Sapporo
Hyogo Cancer Center, Akashi
Kansai Rosai Hospital, Amagasaki
Kobe City Medical Center General Hospital, Kobe
Ibaraki Prefectural Central Hospital, Kasama
Kanazawa University Hospital, Kanazawa
Iwate Medical University Hospital, Shiwa-gun
Kagawa University Hospital, Kita
St. Marianna University School of Medicine Hospital, Kawasaki
The Kitasato Institute Kitasato University Hospital, Sagamihara
Yokohama City University Medical Center, Yokohama
Kanagawa Cancer Center, Yokohama
Japanese Red Cross Kyoto Daini Hospital, Kamigyō-ku
Miyagi Cancer Center, Natori-shi
Osaki Citizen Hospital, Ōsaki
Osaka University Hospital, Suita
Toyonaka Municipal Hospital, Toyonaka
Tochigi Cancer Center, Utsunomiya
Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku
National Cancer Center Hospital, Chuo Ku
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku
Showa University Koto Toyosu Hospital, Koto-Ku
Toranomon Hospital, Minato-Ku
Chiba Cancer Center, Chiba
Fukui Prefectural Hospital, Fukui
National Hospital Organization Kyushu Cancer Center, Fukuoka
Kyushu University Hospital, Fukuoka
Gifu University Hospital, Gifu
Hiroshima City Asa Citizens Hospital, Hiroshima
Hiroshima Prefectural Hospital, Hiroshima
Kochi Health Sciences Center, Kochi
Niigata Cancer Center Hospital, Niigata
Okayama University Hospital, Okayama
Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital, Osaka
Osaka International Cancer Institute, Osaka
Osaka General Medical Center, Osaka
Kindai University Hospital, Osaka
Saitama Cancer Center, Saitama
Shizuoka Cancer Center, Shizuoka
Shizuoka General Hospital, Shizuoka
Keio University Hospital, Tokyo
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Gangnam Severance Hospital, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Chung-Ang University Hospital, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Daiichi Sankyo Co., Ltd.
INDUSTRY